S. Rottey MD, PhD

Highlights in genitourinary cancers

Summary

From June 3^rd till June 8^th, Chicago was host for the 52^nd ASCO annual meeting. The theme for this year’s venue was ‘Collective Wisdom: The Future of Patient-Centred Care and Research’. With almost 35,000 registered attendees from over 100 countries worldwide and about 6,000 submitted abstracts, this year’s meeting was a great success. This report will highlight 10 key studies concerning genitourinary cancers presented during the meeting.

(BELG J MED ONCOL 2016; 10(5): 162–169)

Highlights in genitourinary cancers

From the 25^th till the 29^th of September, Vienna was host for the 18^th ECCO – 40th ESMO European Cancer Congress. Immunotherapy was a very important theme for this year’s venue which hosted 18.500 registered attendees. This report will highlight 4 key studies concerning renal cell carcinoma and metastatic prostate cancer presented during the presidential sessions of the meeting.

(BELG J MED ONCOL 2015;9:244–49)

Highlights in genitourinary cancers

From May 29^th till June 2^nd, Chicago was host for the 2015 ASCO annual meeting. The theme for this year’s congress was ‘Illumination and Innovation: Transforming Data into Learning’. With over 30,000 registered attendees from over 120 countries worldwide and more than 6,000 submitted abstracts, this year’s meeting was a great success. This report will highlight 12 key studies concerning genitourinary cancers presented during the meeting.

(BELG J MED ONCOL 2015;9:158–63)

Second Belgian multidisciplinary meeting on urological cancers held in Brussels – March 28, 2015

Due to the success of last year, a second national Belgian multidisciplinary scientific meeting on urological cancers was held with the cooperation of medical oncologists (BSMO), urologists (BAU) and radiation oncologists (ABRO/BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of urological cancers.
The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (members of BSMO); L. Hoekx, S. Joniau, T. Roumeguere (members of BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (members of ABRO/BVRO). The second meeting, held in Brussels on March 28^th, 2015 was a great success with more than 100 attendees of the different specialisations involved.
In this meeting report you will find summaries of the lectures of Dr De Visschere (Radiologist) and Dr Schrijvers (Medical Oncologist).

(BELG J MED ONCOL 2015;9(3):113–16)

Management and systemic treatment of clear cell metastatic renal cell carcinoma: BSMO expert panel recommendations

Almost 30% of patients with renal cell cancer present initially with advanced stage IV disease. In the past decade, the management of the metastatic renal cell cancer has been revolutionised by the knowledge of its molecular biology and development of targets against vascular endothelial growth factor and mammalian target of rapamycin pathways. In this paper we present recommendations based on a thorough review of available guidelines and data from the phase III randomised controlled trials that evaluated new agents in patients with advanced metastatic renal cancer.
(BELG J MED ONCOL 2015;9(1):16–24)

Highlights in genitourinary cancer

From the 26^th till the 30^th of September, Madrid was host for the 39^th annual congress of the European Society of Medical Oncology (ESMO). The theme of this years’ meeting, that was hosted at the IFEMA – Feria de Madrid, was ‘Precision Medicine in Cancer Care. This report will highlight 10 key studies concerning genitourinary cancers presented during the meeting.

(BELG J MED ONCOL 2014;8(4):143–6)

The first Belgian multidisciplinary meeting on urological cancers

The Belgian multidisciplinary meeting on urological cancers was initiated as the first national multidisciplinary scientific meeting of medical oncologists (BSMO), urologists (BAU) and radiotherapists (ABRO-BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of uro-oncology.

The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (BSMO); L. Hoekx, S. Joniau, T. Roumeguere (BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (ABRO-BVRO). The first meeting, held in Brussels on March 29th, 2014 was a great success with more than 150 attendees of the different specialisations involved.

(BELG J MED ONCOL 2014;8(5):224–7)